Biography for Tracy Staton
Tracy Staton, Senior Editor
Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at firstname.lastname@example.org or find her on LinkedIn.
Articles by Tracy Staton
Here's an earnings trend-buster: Bristol-Myers Squibb trounced expectations for the second quarter and hiked its full-year sales forecast by more than $1 billion.
Roche isn't in denial about oncoming biosimilar competition for its top-selling cancer drugs. But CEO Severin Schwan says its new meds are on track to fill in the gap--and sales growth in the first half of the year go some way toward proving that case.
Johnson & Johnson has heard the advice before: Split up and reap the benefits. This time, it's CNBC's Jim Cramer making the call, and he figures the sum of J&J's parts would be 50% bigger than the whole is now. And he thinks an activist investor might step in and give J&J a push in that direction.
Bristol-Myers Squibb nabbed a "breakthrough" tag from the FDA for its next-gen HIV therapy aimed at patients who become resistant to the drugs now in use.
Worried that health insurers' urge to merge will put even more pressure on your prices? You're in good company. Novartis CEO Joe Jimenez agrees.
Currency hits and a lagging devices business forced down a Big Pharma's second-quarter sales and profits. No, we're not talking about Johnson & Johnson, though the same was true of the U.S.-based health giant. This time, it's Novartis, whose Alcon eye unit proved a drag on strong pharma and generics performance.
Newly independent Baxalta relies heavily on hemophilia sales, particularly its top-selling Advate. As competition heats up in that market, the company has something new to brag about.
Bristol-Myers Squibb can brag about another success with immunotherapy Opdivo. A late-stage study in advanced kidney cancer will be stopped early, after a monitoring committee flagged improved survival results for Opdivo, compared with the Novartis treatment Afinitor.
As payers steer patients toward their own pharmacies and drugmakers opt to distribute their meds solely through specialty channels, service problems are interfering with patient refills and threatening adherence, The New York Times reports.
Amid industry discomfort over current price caps in the country, India's Supreme Court has asked the federal government to take another look at its essential medicines policy. But if the order results in any price changes, they're likely to be in the wrong direction for drugmakers.